MedPage Today on MSN

Cancer drug pulled from market over safety concerns

Confirmatory trial on tazemetostat suggested a link with secondary hematologic malignancie ...
Managed Healthcare Executive

Ipsen removes Tazverik from market and cancels all trials with the blood cancer drug

Ipsen is withdrawing tazemetostat from all markets following signals of secondary hematologic malignancies observed in SYMPHONY-1 evaluating tazemetostat plus lenalidomide/rituximab versus ...
BioSpace

Two AstraZeneca Drugs To Be Scrutinized in First FDA Cancer Advisory Panel in 9 Months

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...
Healio

Safety updates ‘common’ for cancer drugs granted FDA accelerated approval

Please provide your email address to receive an email when new articles are posted on . Most oncology drugs that received FDA accelerated approval between 2011 and 2020 required postmarketing safety ...